Docetaxel for Head and Neck Cancer
Author Information
Author(s): Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, Groult V, Bordessoule S, Janot F, Forni M De, Armand J-P
Primary Institution: Institut Gustave Roussy, Department of Medecine, Villejuif, France
Hypothesis
This study was designed to evaluate the activity, safety and tolerance of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
Conclusion
Docetaxel is active in patients with metastatic squamous cell carcinoma of the head and neck and is well tolerated.
Supporting Evidence
- Twenty-four patients were enrolled in the study.
- Partial responses were achieved in five patients.
- The overall response rate was 20.8%.
- The most frequent side effect was neutropenia, occurring in 79.2% of patients.
Takeaway
This study tested a medicine called docetaxel on people with a type of cancer in their head and neck, and it helped some of them feel better.
Methodology
Twenty-four patients received docetaxel 100 mg m−2 by infusion every 3 weeks, with evaluations for efficacy and toxicity.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
Patients with metastatic squamous cell carcinoma of the head and neck, with no prior palliative therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website